Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer

MF Re-Louhau, M Abad, R Calero - Oncogene, 2014 - nature.com
Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer. Despite
response to chemotherapy, relapses are frequent and resistance to available treatments is …
被引用次数：95 相关文章

Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer

JC Montero, A Esparís-Ogando… - …, 2014 - pubmed.ncbi.nlm.nih.gov
Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer. Despite
response to chemotherapy, relapses are frequent and resistance to available treatments is …

Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.

JC Montero, A Esparís-Ogando, MF Re-Louhau… - …, 2014 - search.ebscohost.com
Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer. Despite
response to chemotherapy, relapses are frequent and resistance to available treatments is …

Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer

JC Montero, A Esparís-Ogando, MF Re-Louhau… - 2012 - digital.csic.es
Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer. Despite
response to chemotherapy, relapses are frequent and resistance to available treatments is …

Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer

JC Montero, A Esparis-Ogando, MF Re-Louhau… - Oncogene, 2014 - go.gale.com
Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer. Despite
response to chemotherapy, relapses are frequent and resistance to available treatments is …
[PDF] researchgate.net

[PDF][PDF] Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer

JC Montero, A Esparıs-Ogando - Oncogene, 2012 - researchgate.net
Triple-negative breast cancer (TNBC) accounts for 15% of all breast cancers. It is defined at
an immunohistochemical level as the lack of detectable expression of hormone receptors …

Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.

JC Montero, A Esparís-Ogando, MF Re-Louhau… - Oncogene, 2012 - europepmc.org
Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer. Despite
response to chemotherapy, relapses are frequent and resistance to available treatments is …

[引用][C] Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer

JC Montero, A Esparís-Ogando, MF Re-Louhau… - Oncogene, 2012 - cir.nii.ac.jp
Active kinase profiling, genetic and pharmacological data define mTOR as an important
common target in triple-negative breast cancer | CiNii Research CiNii 国立情報学研究所 学術 …

[引用][C] Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer

JC Montero, A Esparís-ogando, MF Re-louhau… - …, 2014 - Nature Publishing Group